iX Biopharma Ltd announced on Apr, 17 2026 that it has issued and allotted 1,230,752 new ordinary shares following the exercise of warrants at an exercise price of 0.06 Singapore dollars per share.

The company’s total issued share capital has increased to 1,049,555,281 shares from 1,048,324,529 shares.

To date, 18,795,836 warrants—or 32.68% of the warrants originally issued—have been exercised. A remaining 38,713,643 warrants, each carrying an exercise price of 0.06 Singapore dollars, will expire on Jul, 18 2026.

The newly issued shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 21 2026.